<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Rocuronium</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00728</strong>&#160; (APRD01221)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.<br>
Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is marketed under the trade name of Zemuron in the United States and Esmeron in most other countries.<br>
There is considered to be a risk of allergic reaction to the drug in some patients (particularly those with asthma), but a similar incidence of allergic reactions has been observed by using other members of the same drug class (non-depolarizing neuromuscular blocking drugs). The &#947;-cyclodextrin derivative sugammadex (trade name Bridion) has been recently introduced as a novel agent to reverse the action of rocuronium.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00728/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00728/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00728.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00728.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00728.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00728.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00728.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00728">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Rocuronium bromide</strong>
          <div class="cas">119302-91-9</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000575/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000575/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: OYTJKRAYGYRUJK-FMCCZJBLSA-M</li>
              <li>Monoisotopic Mass: 608.318870841</li>
              <li>Average Mass: 609.678</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000575">DBSALT000575</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Esmeron</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zemuron</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/muscle-relaxant-skeletal">Muscle relaxant, Skeletal</a></li></ul></td></tr><tr><th>CAS number</th><td>143558-00-3</td></tr><tr><th>Weight</th><td>Average: 529.7742<br>Monoisotopic: 529.400533194</td></tr><tr><th>Chemical Formula</th><td>C<sub>32</sub>H<sub>53</sub>N<sub>2</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>YXRDKMPIGHSVRX-OOJCLDBCSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-14-(acetyloxy)-5-hydroxy-2,15-dimethyl-4-(morpholin-4-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-(prop-2-en-1-yl)pyrrolidin-1-ium</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Steroid Esters</td></tr><tr><th>Direct parent</th><td>Steroid Esters</td></tr><tr><th>Alternative parents</th><td>Androgens and Derivatives; Hydroxysteroids; Cyclohexanols; Morpholines; Pyrrolidines; Tertiary Amines; Cyclic Alcohols and Derivatives; Carboxylic Acid Esters; Enolates; Polyamines; Ethers</td></tr><tr><th>Substituents</th><td>3-hydroxy-steroid; cyclohexanol; morpholine; oxazinane; pyrrolidine; cyclic alcohol; secondary alcohol; tertiary amine; carboxylic acid ester; polyamine; enolate; carboxylic acid derivative; ether; alcohol; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the steroid esters. These are compounds containing a steroid moeity which bears a carboxylic acid ester group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.</td></tr><tr><th>Pharmacodynamics</th><td>Neuromuscular blocking agents are drugs that cause skeletal muscle relaxation primarily by causing a decreased response to the neurotransmitter acetylcholine (ACh) at the myoneural (neuromuscular) junction of skeletal muscle. At that site, ACh normally produces electrical depolarization of the postjunctional membrane of motor end-plate, which leads to conduction of muscle action potential and subsequently induces skeletal muscle contraction. Neuromuscular agents are classified as depolarizing or nondepolarizing. Rocuronium is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. Rocuronium, like vecuronium is longer acting in infants than in children. However, unlike vecuronium, rocuronium retains the characteristics of an intermediate-acting NMBD in infants.</td></tr><tr><th>Mechanism of action</th><td>Rocuronium acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium. Rocuronium acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur. Evidence also suggests that nondepolarizing agents can affect ACh release. It has been hypothesized that nondepolarzing agents bind to postjunctional ("curare") receptors and may therefore interfere with the sodium and potassium flux, which is responsible for depolarization and repolarization of the membranes involved in muscle contraction. </td></tr><tr><th>Absorption</th><td>Poorly absorbed from the GI tract.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>0.3 L/kg [3 to &lt;12 mos]</li>
	<li>0.26 L/kg [1 to &lt;3 yrs]</li>
	<li>0.21 L/kg [3 to &lt;8 yrs]</li>
</ul></td></tr><tr><th>Protein binding</th><td>Approximately 30% bound to human plasma proteins.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Rocuronium is metabolized to a less active metabolite, 17-desacetyl-rocuronium, and is eliminated primarily by the liver.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Rocuronium</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00673">17-desacetyl-rocuronium</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/694">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Studies of distribution, metabolism, and excretion in cats and dogs indicate that rocuronium is eliminated primarily by the liver.</td></tr><tr><th>Half life</th><td>The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.</td></tr><tr><th>Clearance</th><td><ul>
	<li>0.25 L/kg/hr [Adults (Ages 27 to 58 years)]</li>
	<li>0.21 L/kg/hr [Geriatrics (&gt;=65 yrs)]</li>
	<li>0.16 L/kg/hr [Normal ewnal and hepatice function]</li>
	<li>0.13 L/kg/hr [Renal transplant patients]</li>
	<li>0.13 L/kg/hr [Hepatic dysfunction patients]</li>
	<li>0.35 +/- 0.08 L/kg/hr [Pediatric Patients 3 to &lt;12 mos]</li>
	<li>0.32 +/- 0.07 L/kg/hr [Pediatric Patients 1 to 3 yrs]</li>
	<li>0.44 +/- 0.16 L/kg/hr [Pediatric Patients 3 to 8 yrs]</li>
</ul></td></tr><tr><th>Toxicity</th><td>No cases of significant accidental or intentional overdose have been reported. Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.9444</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8569</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5336</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8559</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7889</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.9009</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7222</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8008</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7534</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7272</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9103</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8856</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8763</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8423</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8582</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9119</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7601
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9353
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.946
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9310 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8607
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8146
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>App pharmaceuticals llc</li>
<li>Bioniche pharma usa llc</li>
<li>Hospira inc</li>
<li>Sagent pharmaceuticals inc</li>
<li>Sandoz canada inc</li>
<li>Teva parenteral medicines inc</li>
<li>Schering corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.generamedix.com">Generamedix Inc.</a></li>
<li><a href="http://www.glandpharma.com">Gland Pharma Ltd.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.organonshop.com">Organon Pharmaceuticals</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00479">Amikacin</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01190">Clindamycin</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01111">Colistimethate</a></td><td>Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).</td></tr><tr><td><a href="/drugs/DB00798">Gentamicin</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01627">Lincomycin</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00955">Netilmicin</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00319">Piperacillin</a></td><td>The agent increases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>The agent increases the effect of the muscle relaxant</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>